A new plant-derived drug, EBC-46, was associated with regression or palliation in cancerous tumors in four Tasmanian devils, which have suffered massive losses to a contagious cancer. Veterinarian Jack Ayerbe, a director with the company that developed the drug, says he's used it successfully to treat some dogs and cats in his practice. Veterinarian Stephen Pyecroft, who helped develop and test the drug, says it may help treat captive devils and improve survival of their young, but it won't be a feasible treatment for wild animals. Human trials are planned as well.
Published in Brief: